Quantum biopharma signs an agreement with ingenu cro to conduct a clinical study to observe disease progression in patients with primary progressive multiple sclerosis

Toronto, on / accesswire / september 9, 2024 / quantum biopharma ltd. (nasdaq:qntm)(cse:qntm)(fra:0k91) ("quantum biopharma" or the "company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, huge biopharma australia pty ltd.
QNTM Ratings Summary
QNTM Quant Ranking